menu
    • menu
    [{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","graph1":"Genetic Disease","graph2":"Approved","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"12","companyTruncated":"QOL Medical \/ Optum Frontier Therapies"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","graph1":"Genetic Disease","graph2":"Approved","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"QOL Medical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by QOL Medical

    Menu

    QOL Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            QOL Medical

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            QOL Medical, LLC Receives FDA Approval of Sucraid® (sacrosidase) Oral Solution Single-Use Containers for Pati...

                            Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

                            Brand Name : Sucraid

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 06, 2022

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            QOL Medical

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            QOL Medical

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Optum Frontier Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital ...

                            Details : Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

                            Brand Name : Sucraid

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 15, 2022

                            Lead Product(s) : Sacrosidase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Optum Frontier Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth